UK markets open in 5 hours 58 minutes
  • NIKKEI 225

    28,768.08
    +312.48 (+1.10%)
     
  • HANG SENG

    23,993.22
    +9.56 (+0.04%)
     
  • CRUDE OIL

    71.76
    -0.29 (-0.40%)
     
  • GOLD FUTURES

    1,788.10
    +3.40 (+0.19%)
     
  • DOW

    35,719.43
    +492.40 (+1.40%)
     
  • BTC-GBP

    38,120.88
    -333.37 (-0.87%)
     
  • CMC Crypto 200

    1,304.03
    -17.25 (-1.31%)
     
  • ^IXIC

    15,686.92
    +461.76 (+3.03%)
     
  • ^FTAS

    4,178.76
    +61.16 (+1.49%)
     

Vaccitech to Present at the Jefferies London Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

OXFORD, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that Bill Enright, Chief Executive Officer, will be presenting at the Jefferies London Healthcare Conference.

Event:

Jefferies London Healthcare Conference

Presentation:

In person and webcast fireside chat

Date:

November 17

Time:
Webcast:

8 a.m. GMT (3 a.m. EST)
Events section of the Vaccitech website

An audio webcast of each presentation can be accessed through the Events section of the Company's website at https://investors.vaccitech.co.uk/news-and-events/events. An archived replay of each webcast will also be available on the Company's website.

About Vaccitech plc
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable tolerability profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.

Vaccitech Media contacts:
Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: katja@sciuscommunications.com

Robert Flamm, Ph.D. / Harrison Wong, Burns McClellan, Inc. (US)
212-213-0006 ext. 364 / 316
Email: rflamm@burnsmc.com / hwong@burnsmc.com

Henry Hodge, Vaccitech
Email: henry.hodge@vaccitech.co.uk


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting